Showing 708 results
-
Media Release /- 83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data- Data evaluating 63…
-
Media Release /
-
Media Release /-- At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff-- Best ORR was 59%, with 43…
-
Media Release /
-
Media Release /Physicians now have the option of prescribing Kisqali and Femara together in one convenient co-pack Co-Pack allows patients ability to obtain Kisqali and Femara with a single co-pay Approval comes…
-
Media Release /
-
Media Release /Novartis and Amgen to co-commercialize AMG 334 (erenumab) in the U.S.; Novartis to gain exclusive rights in CanadaNovartis retains commercial rights in rest of world; Amgen retains commercial rights…
-
Media Release /
-
Media Release /-- Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)-- R/r DLBCL, an…
-
Media Release /
